Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
| Title: | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
|---|---|
| Patent Number: | 9,066,940 |
| Publication Date: | June 30, 2015 |
| Appl. No: | 13/147194 |
| Application Filed: | February 05, 2010 |
| Abstract: | The present invention relates in general to the field of modulators of the innate immune system, particularly to pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof, preferably suitable for local administration, such as, intravesical administration. In addition, the present invention concerns the use of imidazoquinolin(amines) and derivatives thereof for intravesical treatment of bladder diseases, such as, for example, bladder cancer and cystitis. The present invention furthermore comprises methods of treatment for these diseases as well as methods of administration of the inventive pharmaceutical compositions. |
| Inventors: | Leoni, Lorenzo (Lodrino, CH); Maj, Roberto (Saronno, IT); Pattarino, Franco (Turin, IT); Vecchio, Carlo (Veruno, IT) |
| Assignees: | TELORMEDIX, SA (Bioggio, CH) |
| Claim: | 1. A pharmaceutical composition comprising imiquimod, lactic acid, a polymer and cyclodextrin, wherein the polymer consists of Poloxamer 407 in an amount of 11% (w/v) to 18% (w/v), and the composition is for bladder instillation. |
| Claim: | 2. The pharmaceutical composition of claim 1 , wherein the lactic acid is at a concentration of about 0.025 M to about 0.200 M. |
| Claim: | 3. The pharmaceutical composition of claim 2 , wherein the lactic acid is at a concentration of about 0.075 M to about 0.125 M. |
| Claim: | 4. The pharmaceutical composition of claim 1 , wherein the imiquimod is in an amount of about 0.005% (w/v) to about 5% (w/v). |
| Claim: | 5. The pharmaceutical composition of claim 4 , wherein the imiquimod is in an amount of about 0.1% (w/v) to about 1% (w/v). |
| Claim: | 6. The pharmaceutical composition of claim 1 , wherein the cyclodextrin is selected from α-cyclodextrins, β-cyclodextrins, γ-cyclodextrins, δ-cyclodextrins, ε-cyclodextrins, and hydroxypropyl-β-cyclodextrin (HP-β-CD). |
| Claim: | 7. The pharmaceutical composition of claim 6 , wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD). |
| Claim: | 8. The pharmaceutical composition of claim 1 , wherein the cyclodextrin in an amount of about 0.1% (w/v) to about 30% (w/v). |
| Claim: | 9. The pharmaceutical composition of claim 8 , wherein the cyclodextrin in an amount of about 2% (w/v) to about 6% (w/v). |
| Claim: | 10. The pharmaceutical composition of claim 1 , wherein the Poloxamer 407 is in an amount of 11% (w/v) to 17% (w/v). |
| Claim: | 11. The pharmaceutical composition of claim 10 , wherein the Poloxamer 407 is in an amount of 11% (w/v) to 16% (w/v). |
| Claim: | 12. The pharmaceutical composition of claim 1 , wherein the composition is aqueous. |
| Claim: | 13. A pharmaceutical composition comprising imiquimod in an amount of about 0.1% (w/v) to about 1% (w/v), lactic acid in a concentration of about 0.075 M to about 0.125 M, cyclodextrin in an amount of about 2% (w/v) to about 6% (w/v), and a polymer consisting of Poloxamer 407 in an amount of 11% (w/v) to 18% (w/v), and the composition is aqueous and is for bladder instillation. |
| Patent References Cited: | 4689338 August 1987 Gerster et al. 4727064 February 1988 Pitha 4929624 May 1990 Gerster et al. 4938949 July 1990 Borch et al. 5037986 August 1991 Gerster 5175296 December 1992 Gerster 5238944 August 1993 Wick et al. 5352784 October 1994 Nikolaides et al. 5367076 November 1994 Gerster 5395937 March 1995 Nikolaides et al. 5444065 August 1995 Nikolaides et al. 5624677 April 1997 El-Rashidy et al. 5627281 May 1997 Nikolaides et al. 5648516 July 1997 Nikolaides et al. 5693811 December 1997 Lindstrom 5736553 April 1998 Wick et al. 5741908 April 1998 Gerster et al. 5998619 December 1999 Gerster et al. 6038505 March 2000 Probst et al. 6039969 March 2000 Tomai et al. 6083505 July 2000 Miller et al. 6150523 November 2000 Gerster et al. 6200592 March 2001 Tomai et al. 6245776 June 2001 Skwiercynski et al. 6329381 December 2001 Kurimoto et al. 6333331 December 2001 Moschel et al. 6407079 June 2002 Muller et al. 6437131 August 2002 Gerster et al. 6486168 November 2002 Skwierczynski et al. 6534654 March 2003 Gerster et al. 6552192 April 2003 Hanus et al. 6610319 August 2003 Tomai et al. 6613902 September 2003 Gerster et al. 6624305 September 2003 Gerster 6696076 February 2004 Tomai et al. 6706728 March 2004 Hedenstrom et al. 6716840 April 2004 Chu et al. 6733764 May 2004 Martin 6734187 May 2004 Tanaka et al. 6897314 May 2005 Gerster et al. 6960582 November 2005 Boyce et al. 7001609 February 2006 Matson et al. 7157465 January 2007 Isobe et al. 7189727 March 2007 Boyce 7241890 July 2007 Kasibhatla et al. 7521454 April 2009 Isobe et al. 7655672 February 2010 Statham et al. 2002/0127224 September 2002 Chen 2002/0193595 December 2002 Chu et al. 2003/0187261 October 2003 Havlicek et al. 2003/0191086 October 2003 Hanus et al. 2004/0023211 February 2004 Groen et al. 2004/0132748 July 2004 Isobe et al. 2004/0202663 October 2004 Hu et al. 2004/0248895 December 2004 Chu et al. 2004/0265351 December 2004 Miller et al. 2005/0004144 January 2005 Carson et al. 2005/0038027 February 2005 Boyce 2005/0049263 March 2005 Kasibhatla et al. 2005/0054590 March 2005 Averett 2005/0059613 March 2005 Memarzadeh et al. 2005/0266067 December 2005 Sengupta et al. 2006/0052403 March 2006 Isobe et al. 2006/0110746 May 2006 Andre et al. 2007/0037832 February 2007 Isobe et al. 2007/0087009 April 2007 Burdin 2007/0100146 May 2007 Dzwiniel 2007/0161582 July 2007 Mijikovic et al. 2007/0173483 July 2007 Kasibhatla et al. 2007/0264317 November 2007 Yosha et al. 2007/0292418 December 2007 Fields et al. 2008/0008682 January 2008 Chong et al. 2008/0125446 May 2008 Kasibhatla et al. 2008/0207674 August 2008 Stoesz et al. 2008/0214580 September 2008 Neagu et al. 2009/0047249 February 2009 Graupe et al. 2009/0053186 February 2009 Hu et al. 2009/0069289 March 2009 Neagu et al. 2009/0105212 April 2009 Isobe et al. 2009/0118263 May 2009 Hashimoto et al. 2009/0131458 May 2009 Lazarides et al. 2009/0182004 July 2009 Winckle et al. 2009/0202484 August 2009 Chong et al. 2009/0202626 August 2009 Carson et al. 2009/0263470 October 2009 Coller et al. 2009/0324551 December 2009 Carson et al. 2011/0098294 April 2011 Carson et al. 2013/0237561 September 2013 Leoni et al. 101129373 February 2008 101230064 July 2008 101239980 August 2008 0145340 June 1985 0310950 April 1989 0389302 September 1990 0394026 October 1990 0553202 August 1993 0575549 December 1993 0636031 February 1995 0681570 November 1995 0708773 May 1996 0912564 May 1999 0912565 May 1999 0938315 September 1999 1035123 September 2000 1550662 July 2005 1182208 July 2007 1939202 July 2008 2259788 February 2010 2259788 December 2010 11193282 July 1999 2000159767 June 2000 2001213867 August 2001 2004137157 May 2004 2005089334 April 2005 2006/519784 August 2006 WO 85/02767 July 1985 WO 92/15581 September 1992 WO 93/20847 October 1993 WO 98/17279 April 1998 WO 98/48805 November 1998 WO 99/24432 May 1999 WO 99/28321 June 1999 WO 00/40228 July 2000 WO 00/43394 July 2000 WO 01/19320 March 2001 WO 01/49688 July 2001 WO 02/24225 March 2002 WO 02/081443 October 2002 WO 02/085905 October 2002 WO 03/037860 May 2003 WO 03/077944 September 2003 WO 2004/029054 April 2004 WO 2004/032829 April 2004 WO 2004/066947 August 2004 WO 2005/011708 February 2005 WO 2005/020892 March 2005 WO 2005/025583 March 2005 WO 2005/060966 July 2005 WO 2005/092892 October 2005 WO 2006/087538 August 2006 WO 2006/100226 September 2006 WO 2006/117670 November 2006 WO 2007/015877 February 2007 WO 2007/024707 March 2007 WO 2007/034817 March 2007 WO 2007/034881 March 2007 WO 2007/034882 March 2007 WO 2007/034917 March 2007 WO 2007/038720 April 2007 WO 2007/041863 April 2007 WO 2007/142755 December 2007 WO 2008/005555 January 2008 WO 2008/043031 April 2008 WO 2008/045529 April 2008 WO 2008/101867 August 2008 WO 2008/114008 September 2008 WO 2008/114817 September 2008 WO 2008/115319 September 2008 2008/118763 October 2008 WO 2009/005687 January 2009 WO 2009/034386 March 2009 WO 2009/035634 March 2009 WO 2009/091541 July 2009 2009/099650 August 2009 WO 2009/099650 August 2009 WO 2009/143457 November 2009 WO 2010/089128 August 2010 WO 2010/093436 August 2010 WO 2011/017611 February 2011 WO 2011/139348 November 2011 |
| Other References: | Dumortier et al. “A Review of Poloxamer 407 Pharmaceutical and Pharmacological Characteristics”. Pharmaceutical Research, vol. 23, No. 12, Dec. 2006. cited by examiner Database WPI, Section Ch, Week 200870, Thomson Scientific, London, GB, Feb. 27, 2008. cited by applicant Smith et al., “Antitumor Effects of Imidazoquinolines in Urothelial Cell Carcinoma of the Bladder,” the Journal of Urology, vol. 177, pp. 2347-2351, Jun. 2007. cited by applicant Julien, R.M., Chapter 2: Pharmacodynamics: How Drugs Act, A Primer of Drug Action, (Ninth Edition); Worth Publishers, (2001), pp. 37-57. cited by applicant Lippard et al., “Chemical Synthesis: The art of chemistry,” Nature, 416, (2002), p. 587. cited by applicant “I. Pharmaceutical Importance of Crystallin Hydrates”, [online]. [retrieved on May 30, 2008]. Retrieved from the Internet: Akazawa et al., “Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice.” Cancer research. 2004; 64: 757-764. cited by applicant Alexandroff et al., “BCG immunotherapy of bladder cancer: 20 years on” Lancet 1999; 353: 1689-1694. cited by applicant Anderson et al., “Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels,”J Control Release. 2001; 70: 157-167. cited by applicant Arentsen et al., “Pharmacokinetics and Toxicity of Intravesical TMX-101: A Preclinical Study in Pigs,” The Journal of Urology, e380, vol. 183, No. 4, Supplement, Monday 31, 2010. cited by applicant Atkins et al., “Polarisation of a T-helper cell immune response by activation of dendritic cells with CpGcontaining oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy.” British journal of cancer. 2003; 89: 2312-2319. cited by applicant Babjuk et al; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-314. cited by applicant Baenziger et al., “Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology”, Blood, 113(2), (Jan. 8, 2009), 377-388. cited by applicant Barnetson RS, Satchel A, Zhuang L, Slade HB, Halliday GM. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clinical and experimental dermatology,2004; 29: 639-43). cited by applicant Bilensoy et al., “Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex,” AAPS PharmSciTech. 2006; June 7(2) E54-E60. cited by applicant Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. The Journal of urology. 2003; 170: 964-969. cited by applicant Brewster et al., “Cyclodextrins as pharmaceutical solubilizers.” Advanced drug delivery reviews. 2007; 59: 645-666. cited by applicant Bryan et al., “Interferon (IFN) and IFN Inducers Protect Mouse Bladder Urothelium Against Carcinogenicity by FANFT”, Journal of Cancer Research and Clinical Oncolog˜, 116(Suppl. Part 1), (Abstract A3.1 06.36), (15th International Cancer Congress, Hamburg, Aug. 16-22, 1990), (1990), p. 308. cited by applicant Cabana et al, Study of the Gelation Process of Polyethylene Oxide-polypropylene Oxide-Polyethylene Oxide Copolymer (Poloxamer 407) Aqueous Solutions, J. Colloid Interface Sci. 190, 307-312 (1997). cited by applicant De Boer et al., “Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.” The Journal of urology. 2003; 170: 2004-2008. cited by applicant Carson, D. A., et al., “TLR Agonists”, U.S. Appl. No. 60/710,337, filed Aug. 22, 2005, 52 pgs. cited by applicant Chan et al., “Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates,” Bioconjug Chem. Jun. 2009;20(6):1194-1200. cited by applicant Chang et al., “Prolonged antifungal effects of clotrimazole containing mucoadhesive thermosensitive gels on vaginitis.” J Control Release. 2002; 82: 39-50. cited by applicant Chang Yuchi C et al., Current and potential uses of imiquimod, Southern Medical journal, Southern Medical Association, US, vol. 98, No. 9, Sep. 2005, pp. 913-919. cited by applicant Chollet et al., “Development of a Topically Active Imiquimod Formulation,” Pharmaceutical Development and Technology, 4(1), 35-43, 1999. cited by applicant Clarke et al., “Comparison of Rat and Human Response to Toll-like Receptor 7 Activation,” Journal of Interferon & Cytokine Research (2009), 29(2), 113-126. cited by applicant Colombo et. al., “Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience.,” Critical Reviews in Oncology/Hematology, 2003, Elsevier, vol. 47, pp. 127-139. cited by applicant De Jager et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology. 1991; 38: 507-13. cited by applicant Dharmapuri et al., “An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models,” Cancer Gene Therapy, (2009) 16(5), 462-472. cited by applicant Dolan et al., “Metabolism of 06-benzylguanine, an inactivator of 06-alkylguanine-DNA alkyltransferase.”, Cancer Res., 54(19), (Oct. 1, 1994),5123-30. cited by applicant Games J. Nursing implications in the management of superficial bladder cancer. Seminars in urologic oncology.: 1996; 14: 36-40. cited by applicant Geisse J, Caro I, Lindholm 1, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-733. cited by applicant Geng et al., “Exploring 9-benzyl purines as inhibitors of glutamate racemase (Murl) in Gram-positive bacteria,” Bioorganic & Medicinal Chemistry Letters (2008), 18(15), 4368-4372. cited by applicant Hasan et al., “Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88,” The Journal of Immunology, 2005, 174: 2942-2950. cited by applicant Hayashi et al. Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7. Am J Physiol Regullntegr Comp Physio/. 2008; 295: R123-32). cited by applicant Hayashi et al., “Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7,” PNAS USA (2009), 106(8), 2764-2769. cited by applicant Hegele et al., “Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.” Anticancer research. 2004; 24: 2225-30. cited by applicant Hengge U et al., Topical immunomodulators—progress towards treating inflammation, infaction, and cancer, Lancet Infectious Diseases, Elsevier Ltd., US, vol. 1, No. 3, Oct. 2001, pp. 189-198. cited by applicant Jin, G., et al., “Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists.”, Bioorg Med Chem Lett., 16(17), (Sep. 1, 2006), 4559-63. cited by applicant Kawai, T. and S. Akira (2006). “TLR signalling.” Cell Death Differ 13(5): 816-825. cited by applicant Kobayashi et al., “Prepriming: a novel approach to DNA-based vaccination and immunomodulation”, Springer Seminars in Immunopathology, 22(Nos. 1-2), (2000), 8. cited by applicant Kulikov et. al., Pharmaceutical Chemistry Journal, 1997, Springer, vol. 31, No. 4, pp. 173-177. cited by applicant Kurimoto et al., “Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents”, Bioorg Med Chem., 11(24), (Dec. 1, 2003),5501-8. cited by applicant Lee et al., “Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7”, Proc. Natl. Acad. Sci., 100(11), (2003), 6646-6651. cited by applicant Liu et al., “Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.” BJU Int 2008; 101 :894-901. cited by applicant Luo et al., “Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect,” Cytokine. 2003; 21: 17-26. cited by applicant Malmstrom et al., “An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical Mitomycin C versus Bacillus Caimettte-Guerin for non-muscleinvasive bladder cancer,” Eur Urol 2009; 56 (2):247-256. cited by applicant Mangsbo et al., “CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-ell immunity.” J Immunother. 2008; 31: 34-42. cited by applicant Mayer et al., “A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis”, Journal of Uroloav. 173, (2005), 1186-1191. cited by applicant Metzler, David E, “Biosynthesis of triglycerides and phospholipids”, Biochemistry: The Chemical Reactions of Living Cells, (1977), 3 pgs. cited by applicant Miller, R L, et al., “Imiquimod applied topically: a novel immune response modifier and new class of drug”, IntJ Immunopharmacol., 21(1), (Jan. 1999),1-14. cited by applicant Mosmann, T. R., et al., “TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties”, Annual Review Immunology, 7, (1989), 145-173. cited by applicant Musmuca et al., “Small-Molecule Interferon Inducers. Toward the Comprehension of the Molecular Determinants through Ligand-Based Approaches,” J Chem Inf Model (2009), 49(7) 1777-1786. cited by applicant Purdon CH, Azzi CG, Zhang J, Smith EW, Maibach HI. Penetration enhancement of transdermal delivery-current permutations and limitations. Crit Rev Ther Drug Carrier Syst 2004; 21: 97-132. cited by applicant Rohn et. al., J. Agric. Food Chem., 2004, American Chemical Society, vol. 52, pp. 4725-4729. cited by applicant Saban et al., “Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG),” BMC immunology. 2007; 8: 6. cited by applicant Schenk-Braat EA, Bangma CH. Immunotherapy for \superficial bladder cancer. Cancer ImmunolImmunother. 2005; 54: 414-23. cited by applicant Schoen, Magarete, et al., “Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod”, J Natl Cancer Inst, 95(15), (2003), 1138-1149. cited by applicant Schon MP, Schon M. Zhang (J. Control. Release, 85 (2002) 73-81)Imiquimod: mode of action. Br J Dermatol2007;157:8-13. cited by applicant Sidky. Y. A. et al.. “Curative effectiveness of the interferon inducing imiquimod as a signal agent in mouse bladder tumors”. (Abstract 2789). Proceedings, Eighty-Fourth Meeting of the American Association for Cancer Research, vol. 34. (May 19-22, 1993. Orlando. FL), (Mar. 1993). p. 467. cited by applicant Sidky, Y. A, et al., “Inhibition of Murine Tumor Growth by an Interferon-Inducing Imidazoquinolinamine”. Cancer Research, 52. (1992). 3528-3533. cited by applicant Sidky. Y. A. et al.. “Effects of Treatment with an Oral Interferon Inducer. Imidazoquinolinamine (R-837). on the Growth of Mouse Bladder Carcinoma FCB”. (Abstract 116-12). Journal of Interferon Research, vol. 10, SUI2I2Iement 1. (Annual Meeting of the ISIR. San Francisco, CA. Nov. 14-18, 1990). (Nov. 1990). p. S123. cited by applicant Sidky. Y. A. et al.. “Effects of treatment with the oral interferon inducer. R-837. on the growth of mouse colon carcinoma. MC-26”. (Abstract 2574). Proceedings, 81st Annual Meeting of the American Association for Cancer Research, vol. 31, (Mar. 1990), p. 433. cited by applicant Sidky. Y. A. et al.. “Inhibition of tumor-induced angiogenesis by the interferon inducer Imiquimod”.(Abstract 458) Proceedings, Eighty-Third Annual Meeting of the American Association of Cancer Research, vol. 33. (May 20-23, 1992. San Diego, CA). (Mar. 1992), p. 77. cited by applicant Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urologic oncology. 2008; 26: 341-345. cited by applicant Simons. M. P .. et al., “Identification of the Mycobacterial Subcomponents Involved in the Release of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand from Human Neutrophils”. (Abstract 458). Infection and Immunity 75(3). (2007). 1265-1271. cited by applicant Smith et al., Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder, J Urol. Jun. 2007;177(6):2347-2351. cited by applicant Smith et al., “Effects of imiquimod, a toll-like receptor-7 agonist on cell proliferation and cytokine production in bladder cancer in vitro and in vivo,” Journal of Urology, vol. 173, No. 4, Suppl. S, Apr. 2005, p. 158 & Annual Meeting of the American-Urological-Association, San Antonio, TX, USA; May 21-26, 2005. cited by applicant Suttmann H, Riemensberger J, Bentien G et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer research. 2006; 66: 8250-7. cited by applicant Sylvester FJ, Van der Meijden AP, Lamm DL. intravesical bacillus Calmetie-Guerin reduces the risk of progression in patients with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials. J Urol 2002; 168:196470. cited by applicant Totterman TH, Loskog A, Essand M. The immunotherapy of prostate and bladder cancer. BJU international 2005; 96: 728-735. cited by applicant Veronese, F. M., et al., “The impact of PEGylation on biological therapies”, SioDrugs, 22(5), (2008), 315-329. cited by applicant Vultaggio et al., “Modified Adenine (9-Benzyl-2-Butoxy-8-Hydroxyadenine) Redirects Th2-Mediated Murine Lung Inflammation by Triggering TLD7,” Journal of Immunology (2009), 182(2), 880-889. cited by applicant Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007; 67: 2187-210. cited by applicant Weterings et al., “2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation,” Bioorganic & Medicinal Chemistry Letters (2009), 19(8), 2249-2251. cited by applicant Wille-Reece, U .. et al.. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates . . . Proc. Natl. Acad. Sci. USA, 102(42}, (Oct. 18, 2005).15190-15194. cited by applicant Witjes JA, Palou J, Soloway M, Lamm 0, Brausi M, Spermon JR, Persad R, Buckley R, Akaza H, Colombel M, Bohle A. Clinical Practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur. Urol Suppl2008;7:667-674. cited by applicant Witt PL, Ritch PS, Reding, McAuliffe TL, Westrick L, Grossberg SE, Borden EC. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993;53:5176-5180. cited by applicant Wu et al., “Immunotherapeudic activity of a conjugate of a Toll-like receptor 7 Ligand,” PNAS USA (2007), 104(10), 3990-3995. cited by applicant Zaks. K. et al.. “Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agoinst complexed to cationic Liposomes”. Journal of Immunology, 176 (12). (Jun. 15, 2006). 7335-7345. cited by applicant Zhang (J. Control. Release, 85 (2002) 73-81). cited by applicant Office Action dated: Apr. 13, 2012 in U.S. Appl. No. 12/367,172, filed Feb. 6, 2009 and published as: US2009/02022626 on Aug. 13, 2009. cited by applicant Office Action dated: Jan. 18, 2012 in U.S. Appl. No. 12/367,172, filed Feb. 6, 2009 and published as: US2009/02022626 on Aug. 13, 2009. cited by applicant Office Action dated: May 27, 2011 in U.S. Appl. No. 12/367,172, filed Feb. 6, 2009 and published as: US2009/02022626 on Aug. 13, 2009. cited by applicant International Preliminary Report on Patentability dated: Nov. 6, 2012 in International Application No. PCT/US2011/000757 filed, Apr. 29, 2011 and published as: WO/2009/099650 on Aug. 13, 2009. cited by applicant International Search Report and Written Opinion dated: Dec. 21, 2011 in International Application No. PCT/US2011/000757 filed, Apr. 29, 2011 and published as: WO/2009/099650 on Aug. 13, 2009. cited by applicant International Preliminary Report on Patentability mailed on: Aug. 9, 2011, in International Application No. PCT/EP2010/000722 filed on Feb. 5, 2010 and published as WO 2010/089128 on Aug. 12, 2010. cited by applicant International Search Report and Written Opinion mailed on: Mar. 9, 2011, in International Application No. PCT/EP2010/000722 filed on Feb. 5, 2010 and published as WO 2010/089128 on Aug. 12, 2010. cited by applicant International Preliminary Report on Patentability mailed on: Jun. 28, 2011, in International Application No. PCT/US2010/000369 filed on Feb. 11, 2010 and published as WO 2010/093436 on Aug. 19, 2010. cited by applicant International Search Report and Written Opinion mailed on: Sep. 21, 2010, in International Application No. PCT/US2010/000369 filed on Feb. 11, 2010 and published as WO 2010/093436 on Aug. 19, 2010. cited by applicant International Preliminary Report on Patentability mailed on: Aug. 10, 2010, in International Application No. PCT/US2009/000771 filed on Feb. 6, 2009 and published as WO 2010/099650 on Aug. 13, 2009. cited by applicant International Search Report and Written Opinion mailed on: Aug. 28, 2009,in International Application No. PCT/US2009/000771 filed on Feb. 6, 2009 and published as WO 2010/099650 on Aug. 13, 2009. cited by applicant International Preliminary Report on Patentability mailed on: Aug. 11, 2009, in International Application No. PCT/US2008/001631 filed on Feb. 7, 2008 and published as WO 2008/115319 on Sep. 25, 2008. cited by applicant International Search Report and Written Opinion mailed on: Jan. 21, 2009, in International Application No. PCT/US2008/001631 filed on Feb. 7, 2008 and published as WO 2008/115319 on Sep. 25, 2008. cited by applicant International Preliminary Report on Patentability mailed on: Dec. 3, 2008, in International Application No. PCT/US2007/009840 filed on Apr. 23, 2008 and published as WO 2007/142755 on Dec. 13, 2007. cited by applicant International Search Report and Written Opinion mailed on: Aug. 5, 2008, in International Application No. PCT/US2007/009840 filed on Apr. 23, 2008 and published as WO 2007/142755 on Dec. 13, 2007. cited by applicant International Preliminary Report on Patentability mailed on: Feb. 26, 2008, in International Application No. PCT/US2006/032371 filed on Aug. 21, 2006 and published as WO 2007/024707 on Mar. 1, 2007. cited by applicant International Search Report and Written Opinion mailed on: Jul. 23, 2007, in International Application No. PCT/US2006/032371 filed on Aug. 21, 2006 and published as WO 2007/024707 on Mar. 1, 2007. cited by applicant Extended European Search Report mailed: Feb. 15, 2011 in European Application Serial No. EP09709019.5, filed Feb. 9, 2009. cited by applicant Extended Search Report mailed: Oct. 24, 2011 in European Application Serial No. 06813535.9, Extended Search Report mailed: Oct. 24, 2011. cited by applicant Office Action mailed on Oct. 17, 2014 in U.S. Appl. No. 13/775,906, filed Feb. 25, 2013 and published as US 2013-0237561 on Sep. 12, 2013. cited by applicant Bonacucina et al., “Effect of hydroxypropyl beta-cyclodextrin on the self-assembling and thermogelation properties of Poloxamer 407” Eur J Pharm Sci (2007) 32(2):115-22. cited by applicant Shaker et al., “In-Situ Injectable Thermosensitive Gel Based on Poloxamer as a New Carrier for Tamoxifen Citrate” International Journal of Pharmacy and Pharmaceutical Sciences (2013) 5(Suppl. 4):429-437. cited by applicant Chen et al., “Mechanical, rheological and release behaviors of a poloxamer 407/poloxamer 188/carbopol 940 thermosensitive composite hydrogel” Molecules (2013) 18:12415-12425. cited by applicant Charrueau et al., “Poloxamer 407 as a thermogelling and adhesive polymer for rectal administration of short-chain fatty acids.” Drug Dev. Ind. Pharm. (2001) 27(4):351-357. cited by applicant Bourre et al., “Potential efficacy of a delta 5-aminolevulinic acid thermosetting gel formulation for use in photodynamic therapy of lesions of the gastrointestinal tract.” Pharmacol. Res. (2002) 45(2):159-165. cited by applicant Shin et al., “Permeation of piroxicam from the poloxamer gels.” Drug Dev. Ind. Pharm. (1999) 25(3):273-278. cited by applicant Fawaz et al., “Comparative in vitro-in vivo study of two quinine rectal gel formulations.” Int. J. Pharm. (2004) 280(1-2):151-162. cited by applicant Hayashi et al., “Intravesical Toll-like receptor 7 agonist R-847; Optimization of its formulation in an orthotopic mouse model of Bladder Cancer”, International Journal of Urology (2010) 17:483-491. cited by applicant Tyagi et al., “Local drug delivery to bladder using technology innovations,” The Urological Clinics of North America, Nov. 2006, vol. 33, No. 4, pp. 519-530. cited by applicant Office Action mailed on Apr. 30, 2014 in U.S. Appl. No. 13/775,906, filed Feb. 25, 2013 and published as US 2013-0237561 on Sep. 12, 2013. cited by applicant Spohn et al., “Synthetic lipopeptide adjuvants and Toll-like receptor 2—structure-activity relationships” Vaccine (2004) 22(19):2494-2499. cited by applicant Shen et al., “Intravesical Treatments of Bladder Cancer: Review” Pharmaceutical Research (2008) 25(7):1500-1510. cited by applicant Wientjes et al., “Bladder Wall Penetration of Intravesical Mitomycin C in Dogs” Cancer Research (1991) 51:4347-4354. cited by applicant |
| Primary Examiner: | Claytor, Renee |
| Attorney, Agent or Firm: | Grant IP, Inc. |
| Accession Number: | edspgr.09066940 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|